Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen (AMGN) Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, inflammation, bone ...

William Blair also expressed optimism about Amgen’s broader portfolio, citing revenue upside potential from key assets including Repatha, Imdelltra, and Uplizna, while success with late-stage ...

Piper Sandler reiterated an Overweight rating on Amgen, citing the success of this cancer treatment as a positive development. William Blair also maintained an Outperform rating, highlighting the ...

William Blair also maintained an Outperform rating, highlighting the potential revenue growth from Amgen’s broader portfolio, including drugs like Repatha and Imdelltra. 3rd party Ad.

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding ...